ArticleTranslational lung cancer research2021
Safety of lorlatinib following alectinib-induced pneumonitis in two patients with
Article in Translational lung cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Incidence of pneumonitis following the use of different anaplastic lymphoma kinase tyrosine kinase inhibitor regimens: An updated systematic review and meta-analysis.Cancer medicine · 2023Pooled it
- Clinical features, diagnosis, and outcome of anaplastic lymphoma kinase tyrosine kinase inhibitors associated interstitial lung disease.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2026Article
- Paradoxical Efficacy With Rare Adverse Events: Sequential ALK Inhibitor Therapy in Lung Adenocarcinoma.Clinical case reports · 2026Article
- Drug-induced eosinophilic pneumonia: a real-world data mining study of the FAERS and Vigibase database reveals potential safety signals and risk patterns.Frontiers in medicine · 2026Article
- Perforation of the descending colon induced by alectinib in a patient with non-small cell lung cancer: a Case Report.Frontiers in pharmacology · 2025Article
- Safety of brigatinib following alectinib-induced-pneumonitis: Case report.Respiratory medicine case reports · 2025Article
- Lorlatinib After Alectinib-Induced Pneumonitis: A Case Report.JTO clinical and research reports · 2024Article
- Post-marketing safety of lorlatinib: a real-world study based on the FDA adverse event reporting system.Frontiers in pharmacology · 2024Article
- Salvage Therapy With Selpercatinib forJTO clinical and research reports · 2023Article
- A non-small cell lung carcinoma patient responded to crizotinib therapy after alectinib-induced interstitial lung disease.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2023Article
- [Early Onset Pulmonary Events and Management Strategies during the Treatment of ALK Positive NSCLC Patients with Brigatinib].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023Article
- Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report.International journal of molecular sciences · 2022Article
- Efficacy of lorlatinib after alectinib-induced interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report.Journal of medical case reports · 2022Article
- Successful Tepotinib Challenge After Capmatinib-Induced Interstitial Lung Disease in a Patient With Lung Adenocarcinoma HarboringJTO clinical and research reports · 2022Article
- Case report: Indolent drug-related pneumonitis with alectinib therapy in the treatment of non-small cell lung cancer.Frontiers in pharmacology · 2022Article
- An Unusual Case of Lorlatinib-Induced Pneumonitis: A Case Report.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-induced interstitial lung disease (DI-ILD) is a rare adverse event associated with targeted therapies that inhibit the anaplastic lymphoma kinase (ALK) protein. Although newer-generation ALK inhibitors such as alectinib significantly improve survival in metastatic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.